Learnings from the 2024 Utah Cardiac Recovery Symposium: A Roadmap for the Field of Myocardial Recovery.
MCS
U-CARS
cardiac recovery
cardiomyocytes
conference proceedings
genetic regulation
heart failure
metabolism
non-cardiomyocyte
Journal
Methodist DeBakey cardiovascular journal
ISSN: 1947-6108
Titre abrégé: Methodist Debakey Cardiovasc J
Pays: United States
ID NLM: 101508600
Informations de publication
Date de publication:
2024
2024
Historique:
received:
03
07
2024
accepted:
04
07
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
The 12th annual Utah Cardiac Recovery Symposium (U-CARS) in 2024 continued its mission to advance cardiac recovery by uniting experts across various fields. The symposium featured key presentations on cutting-edge topics such as CRISPR gene editing for heart failure, guideline-directed medical therapy for heart failure (HF) with improved/recovered ejection fraction (HFimpEF), the role of extracorporeal cardiopulmonary resuscitation (ECPR) in treating cardiac arrest, and others. Discussions explored genetic and metabolic contributions to HF, emphasized the importance of maintaining pharmacotherapy in HFimpEF to prevent relapse, and identified future research directions including refining ECPR protocols, optimizing patient selection, and leveraging genetic insights to enhance therapeutic strategies.
Identifiants
pubmed: 39184165
doi: 10.14797/mdcvj.1443
pmc: PMC11342851
doi:
Types de publication
Congress
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-97Informations de copyright
Copyright: © 2024 The Author(s).
Déclaration de conflit d'intérêts
Dr. Bhimaraj is a consultant for Abbott and Abiomed. Dr. Drakos is a consultant for Abbott, conducts research on behalf of Novartis, National Institutes of Health, US Department of Veterans Affairs, and the American Heart Association, and co-organizes the UCARS conference. The other authors have no competing interests to declare.